September 20, 2019 / 3:44 PM / a month ago

BRIEF-Roche Company Chugai Says Obtained Approval For Additional Indication And Formulation For Tecentriq In Pd-L1-Positive Triple Negative Breast Cancer In Japan

* COMPANY CHUGAI SAYS OBTAINED APPROVAL FOR ADDITIONAL INDICATION AND FORMULATION FOR TECENTRIQ IN PD-L1-POSITIVE TRIPLE NEGATIVE BREAST CANCER IN JAPAN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below